What’s new

• Annual revenue reached ₹120.20 lakhs in FY26.
• Q4 performance accounted for nearly all of the year's revenue, with ₹119.69 lakhs reported.
• Auditors issued an unmodified opinion on the standalone financial statements.

Why it matters

iSERA is transitioning from a period of minimal activity to generating revenue. While the numbers are small, the leap in the final quarter validates the shift toward software and IT services after the recent capital raise.

What we’re watching

• Revenue consistency in the coming quarters.
• Use of funds from the ₹8.08 crore rights issue.
• Operational expenses as the business scales.

The full read

iSERA Lifesciences reported a net profit of ₹25.94 lakhs for FY26, more than doubling the ₹11.81 lakhs earned in the previous year. Revenue for the period hit ₹120.20 lakhs, an increase fueled entirely by a late-year surge. The company booked ₹119.69 lakhs in revenue and ₹34.68 lakhs in profit during Q4 alone. This performance follows the deployment of capital from an ₹8.08 crore rights issue, signaling early success in its move into the software and IT services space. The auditor confirmed the results with an unmodified opinion. For a company that previously operated with near-zero turnover, these figures represent a baseline of activity. The next test for iSERA is to maintain this revenue run-rate in the upcoming quarters.

Primary source: BSE · NSE